Imugene: Serious inroads – a highly successful cancer drug trial 

Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s successful clinical trial of its immunotherapy for stomach cancer that showed material increases in overall survival rates with one patient still showing promising signs over 900 days later. 

Imugene: Serious inroads – a highly successful cancer drug trial 
Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s successful clinical trial of its immunotherapy for stomach cancer that showed material increases in overall survival rates with one patient still showing promising signs over 900 days later.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N’ Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia’s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N&rsquo; Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia&rsquo;s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Advertisement